Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile [Seeking Alpha]
Unicycive Therapeutics, Inc. (UNCY)
Company Research
Source: Seeking Alpha
OLC targets hyperphosphatemia in CKD dialysis patients, offering competitive advantages like lower pill burden, smaller size, and swallowable tablets. The prior FDA rejection was solely due to third-party manufacturing issues, not clinical data, increasing confidence in potential approval. UNCY's $41.3M cash position funds operations into 2027, while pipeline asset UNI-494 could address unmet needs in acute kidney injury. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Thicha Satapitanon/iStock via Getty Images I'm initiating Unicycive Therapeutics ( UNCY ) with a "Buy" rating, and this is based on its ability to have its resubmission of its New Drug Application [NDA] for oxylanthanum carbonate [OLC] accepted by the FDA for review. This drug is a phosphate More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central phar
Show less
Read more
Impact Snapshot
Event Time:
UNCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UNCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UNCY alerts
High impacting Unicycive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
UNCY
News
- UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) ResubmissionGlobeNewswire
- Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission [Yahoo! Finance]Yahoo! Finance
- Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) ResubmissionGlobeNewswire
- Unicycive Therapeutics (NASDAQ:UNCY) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Unicycive resubmits NDA for hyperphosphatemia asset [Seeking Alpha]Seeking Alpha
UNCY
Sec Filings
- 1/23/26 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form 8-K
- UNCY's page on the SEC website